methylphenidate has been researched along with Parkinsonian Disorders in 5 studies
Methylphenidate: A central nervous system stimulant used most commonly in the treatment of ATTENTION DEFICIT DISORDER in children and for NARCOLEPSY. Its mechanisms appear to be similar to those of DEXTROAMPHETAMINE. The d-isomer of this drug is referred to as DEXMETHYLPHENIDATE HYDROCHLORIDE.
methylphenidate : A racemate comprising equimolar amounts of the two threo isomers of methyl phenyl(piperidin-2-yl)acetate. A central stimulant and indirect-acting sympathomimetic, is used (generally as the hydrochloride salt) in the treatment of hyperactivity disorders in children and for the treatment of narcolepsy.
methyl phenyl(piperidin-2-yl)acetate : A amino acid ester that is methyl phenylacetate in which one of the hydrogens alpha to the carbonyl group is replaced by a piperidin-2-yl group.
Parkinsonian Disorders: A group of disorders which feature impaired motor control characterized by bradykinesia, MUSCLE RIGIDITY; TREMOR; and postural instability. Parkinsonian diseases are generally divided into primary parkinsonism (see PARKINSON DISEASE), secondary parkinsonism (see PARKINSON DISEASE, SECONDARY) and inherited forms. These conditions are associated with dysfunction of dopaminergic or closely related motor integration neuronal pathways in the BASAL GANGLIA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The importance of DAT in Parkinson's disease (PD) in which DAT may be reduced by 50 to 70% is unclear." | 2.71 | The dopamine transporter: importance in Parkinson's disease. ( Carter, JH; Nutt, JG; Sexton, GJ, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (20.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Oakes, HV | 1 |
| McWethy, D | 1 |
| Ketchem, S | 1 |
| Tran, L | 1 |
| Phillips, K | 1 |
| Oakley, L | 1 |
| Smeyne, RJ | 1 |
| Pond, BB | 1 |
| Zhang, LL | 1 |
| Canning, SD | 1 |
| Wang, XP | 1 |
| GIBERTI, F | 1 |
| GIANNIOTTI, G | 1 |
| SPIZZIRRI, S | 1 |
| Nutt, JG | 1 |
| Carter, JH | 1 |
| Sexton, GJ | 1 |
| Wüllner, U | 1 |
| Reimold, M | 1 |
| Abele, M | 1 |
| Bürk, K | 1 |
| Minnerop, M | 1 |
| Dohmen, BM | 1 |
| Machulla, HJ | 1 |
| Bares, R | 1 |
| Klockgether, T | 1 |
1 review available for methylphenidate and Parkinsonian Disorders
| Article | Year |
|---|---|
Freezing of Gait in Parkinsonism and its Potential Drug Treatment.
Topics: Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Botulinum Toxins; Droxidopa; Gait Disorde | 2016 |
1 trial available for methylphenidate and Parkinsonian Disorders
| Article | Year |
|---|---|
The dopamine transporter: importance in Parkinson's disease.
Topics: Aged; Analysis of Variance; Blood Pressure; Dopamine Agents; Dopamine Plasma Membrane Transport Prot | 2004 |
3 other studies available for methylphenidate and Parkinsonian Disorders
| Article | Year |
|---|---|
Effect of Chronic Methylphenidate Treatment in a Female Experimental Model of Parkinsonism.
Topics: Animals; Corpus Striatum; Dopamine Uptake Inhibitors; Dopaminergic Neurons; Female; Methylphenidate; | 2021 |
[Further results of new therapy of Parkinsonian syndromes; therapeutic action of 3-phenyl-3-b-diethylamino-ethyl-2-6-dioxy-piperidine hydrochloride administered alone and with reserpine and ritalin].
Topics: Methylphenidate; Parasympatholytics; Parkinson Disease; Parkinsonian Disorders; Piperidines; Reserpi | 1957 |
Dopamine transporter positron emission tomography in spinocerebellar ataxias type 1, 2, 3, and 6.
Topics: Adult; Binding, Competitive; Biomarkers; Brain; Brain Mapping; Dopamine; Dopamine Plasma Membrane Tr | 2005 |